Dr. Roman Salasznyk leads Booz Allen Hamilton‘s life science practice, as well as its support to the US Food & Drug Administration, National Institutes of Health (NIH), and digital programs across the Department of Health & Human Services (HHS) and Military Health.
Based out of the Bethesda, Maryland office, he is a recognised leader in the pharmaceutical development lifecycle. This includes the management of nonclinical, clinical, and manufacturing studies; supporting transformational change through the digital delivery of leading edge informatics capabilities; and integrating broad disciplines within life sciences to support federal health clients.
“We’ve made a concerted effort to invest and provide leading-edge capabilities to support some of our client’s most pressing public health challenges across the federal government space,” says Salasznyk. “Technology must add value, solve a business problem, and deliver measurable improvements in efficiency and effectiveness.”
That efficiency is driven by over 29,000 experts around the world driving digital journeys, developing analytics insights, engineering, and cybersecurity solutions. Booz Allen’s teams work shoulder-to-shoulder with clients to choose the right tech to realise their vision and transform.
Bringing expertise and innovation to FDA product development
Booz Allen has supported the FDA for over 25 years. Today, it is a leading provider of services focused on supporting the modernisation of its IT, data, and business operations, strengthening mission performance, and addressing emerging and strategic priorities across the enterprise.
“Through delivering leading-edge informatics and analytics capabilities, our regulatory scientists and technologists are expediting the approval of innovative new products and personalised medicines, helping the FDA bring life-saving drugs and devices to market more quickly and efficiently,” explains Salasznyk.
During the past year, the Center for Devices and Radiological Health (CDRH) faced unprecedented challenges. The increasing complexity and volume of regulatory submissions, the globalisation of the medical device industry, and workload associated with its COVID-19 response.
To meet these challenges, Booz Allen is currently supporting a multi-year, Digital Transformation Initiative aimed to modernise its IT systems. It will provide enterprise-ready solutions and enabling capabilities to support the needs of industry and its reviewer community. This includes consolidating over 30 legacy IT systems into a modernised platform consisting of an architecture of leading-edge electronic submission, workflow and data management, and business and artificial intelligence capabilities.
